ANSWER: B

Rationale:

Clopidogrel is a thienopyridine prodrug that undergoes two sequential hepatic oxidation steps to generate its active thiol metabolite. The first step involves CYP1A2 and CYP2C19 and produces the intermediate 2-oxo-clopidogrel; the second step — which generates the pharmacologically active thiol — is catalyzed predominantly by CYP2C19, with contributions from CYP3A4, CYP2B6, and CYP2C9. CYP2C19*2 is a splice-site loss-of-function variant that produces a non-functional enzyme; in a CYP2C19*2/*2 homozygous poor metabolizer, the CYP2C19 contribution to both steps is severely impaired, resulting in substantially reduced active thiol metabolite generation. Without adequate active thiol, P2Y12 receptor occupancy and irreversible blockade are insufficient to prevent ADP-mediated platelet activation at the stent surface, explaining this patient's sub-acute stent thrombosis. The FDA issued a boxed warning for clopidogrel in 2010 specifically regarding CYP2C19 poor metabolizer status.

• Option A: Option A is incorrect: while diabetes is associated with platelet hyperreactivity, the primary explanation for this patient's clopidogrel failure is his CYP2C19 poor metabolizer genotype, which is the specific pharmacogenomic mechanism responsible; diabetes does not independently make clopidogrel inadequate for all patients at standard doses.
• Option C: Option C is incorrect: the active thiol metabolite is not primarily renally eliminated, and CYP2C19 poor metabolizer status does not upregulate renal OAT1 transporters; the failure of clopidogrel in poor metabolizers is a hepatic bioactivation deficiency, not an elimination acceleration.
• Option D: Option D is incorrect: CYP2C19*2 is a loss-of-function, not gain-of-function allele; it reduces clopidogrel bioactivation, not active metabolite inactivation; a gain-of-function allele (CYP2C19*17) produces more active metabolite and may increase bleeding risk.

ANSWER: D

Rationale:

The appropriate response to documented CYP2C19 poor metabolizer status with clinical clopidogrel failure is to switch to a P2Y12 inhibitor whose efficacy is not dependent on CYP2C19 bioactivation. Prasugrel undergoes a two-stage activation: intestinal hydrolysis by carboxylesterase 2 (CES2) to a thiolactone intermediate, followed by a single CYP oxidation step predominantly involving CYP3A4 with minor CYP2C19 contribution; the single-step requirement makes prasugrel approximately three times more efficient in active thiol generation and substantially less sensitive to CYP2C19 loss-of-function alleles. This patient at 83 kg with no prior TIA or stroke meets none of the prasugrel contraindications. Ticagrelor requires no CYP bioactivation at all — it is a direct-acting cyclopentyl-triazolo-pyrimidine that binds P2Y12 reversibly at an allosteric site independent of CYP2C19 genotype. Both agents are appropriate and guideline-supported alternatives for CYP2C19 poor metabolizers after clopidogrel failure.

• Option A: Option A is incorrect: doubling clopidogrel dose does not overcome homozygous CYP2C19*2 poor metabolizer status; without functional CYP2C19, providing more prodrug substrate does not generate meaningfully more active thiol; the CURRENT-OASIS 7 doubled-dose benefit did not extend to homozygous poor metabolizers.
• Option B: Option B is incorrect: aspirin monotherapy cannot substitute for P2Y12 inhibition after recent coronary stent placement; the risk of recurrent stent thrombosis on aspirin alone within 3 months of DES placement is unacceptably high.
• Option C: Option C is incorrect: vorapaxar blocks PAR-1 (thrombin receptor) and cannot substitute for P2Y12 inhibition; stent thrombosis prevention requires ADP-pathway blockade at P2Y12; vorapaxar is not a guideline-recommended treatment for clopidogrel failure due to CYP2C19 genotype.

ANSWER: A

Rationale:

CYP2C19 genotyping and platelet function testing (PFT) are complementary rather than competing tools. Genotyping identifies the pharmacokinetic root cause of potential clopidogrel inadequacy — a fixed, inherited characteristic of CYP2C19 enzyme function that does not change with time, is not affected by assay conditions or sample timing, and predicts a lifelong predisposition to impaired clopidogrel bioactivation across all clinical contexts. A CYP2C19*2/*2 result is a permanent, actionable finding that guides P2Y12 inhibitor selection definitively. Platelet function testing measures the pharmacodynamic consequence — the degree of actual P2Y12 receptor blockade achieved — but this measurement is influenced by multiple variables: timing of the assay relative to the last drug dose, patient compliance, assay methodology, concurrent pro-inflammatory states that transiently increase platelet reactivity, and other medications. PFT does not identify why platelet reactivity is high (genotype vs. non-compliance vs. drug interaction). The TAILOR-PCI trial, which prospectively evaluated genotype-guided P2Y12 inhibitor selection, demonstrated that genotyping-guided escalation from clopidogrel to ticagrelor in loss-of-function carriers reduced major adverse cardiovascular events.

• Option B: Option B is incorrect: VerifyNow does not provide 100% sensitivity for stent thrombosis prediction; PFT cannot replace genotyping because it does not identify the cause of residual platelet reactivity; PFT and genotyping provide complementary information and neither has completely replaced the other in guidelines.
• Option C: Option C is incorrect: CYP2C19 genotyping is explicitly recommended as a proactive (pre-event) tool by pharmacogenomic guidelines (CPIC) and is most valuable before a clinical event occurs; waiting for an event defeats the preventive purpose of testing.
• Option D: Option D is incorrect: no randomized trial has demonstrated that routine universal PFT- or genotype-guided P2Y12 selection for all PCI patients reduces stent thrombosis versus standard care; both strategies have evidence supporting their use in selected populations, but neither is currently a universal ACC/AHA Class I recommendation for all-comers.

ANSWER: C

Rationale:

The pharmacokinetic interaction between omeprazole and clopidogrel is mediated by CYP2C19 inhibition reducing clopidogrel bioactivation — a mechanism entirely dependent on clopidogrel being a prodrug requiring CYP2C19-mediated hepatic conversion to its active thiol. Ticagrelor is not a prodrug and does not require CYP2C19 bioactivation; it is absorbed and acts directly as the parent compound, with approximately 30 to 40% of its antiplatelet effect contributed by an active metabolite (AR-C124910XX) generated by CYP3A4, not CYP2C19. Omeprazole's CYP2C19 inhibition therefore has no pharmacologically meaningful effect on ticagrelor's antiplatelet activity. This is a clinically important distinction: the PPI selection concern that existed with clopidogrel does not apply to ticagrelor, and omeprazole co-prescription with ticagrelor does not reduce P2Y12 inhibition. Pantoprazole remains a clinically reasonable choice for consistency with PPI prescribing preferences, but there is no pharmacokinetic mandate to switch from omeprazole when the P2Y12 inhibitor is ticagrelor rather than clopidogrel.

• Option A: Option A is incorrect: ticagrelor's active metabolite AR-C124910XX is generated by CYP3A4, not CYP2C19; CYP2C19 inhibition by omeprazole does not reduce ticagrelor or its active metabolite's plasma concentrations; this option incorrectly attributes CYP2C19 dependence to ticagrelor.
• Option B: Option B is incorrect: omeprazole is a CYP2C19 substrate and inhibitor, not a CYP3A4 inducer; it does not induce CYP3A4 through PXR activation; omeprazole does not accelerate ticagrelor elimination.
• Option D: Option D is incorrect: omeprazole's P-glycoprotein interactions are not clinically significant for ticagrelor bioavailability in the way described; this mechanism does not constitute a recognized drug interaction requiring PPI substitution when ticagrelor is used.

ANSWER: C

Rationale:

Prior stroke or TIA is an absolute contraindication to prasugrel, established in the TRITON-TIMI 38 trial in which patients with prior stroke or TIA who received prasugrel had markedly elevated rates of intracranial hemorrhage that produced net clinical harm. This contraindication is listed in the prasugrel FDA prescribing information as a boxed warning and applies regardless of when the TIA occurred — whether before prasugrel initiation or arising de novo during maintenance therapy. There is no time-qualification caveat, no lookback-period restriction, and no provision for restarting after a defined hold. The correct management is immediate discontinuation of prasugrel and transition to an alternative P2Y12 inhibitor — clopidogrel or ticagrelor — neither of which carries the same TIA/stroke absolute contraindication; a loading dose of the chosen alternative should be given at transition to maintain stent coverage.

• Option A: Option A is incorrect: dose reduction to 5 mg does not resolve the contraindication; the 5 mg dose is indicated for patients weighing less than 60 kg to reduce bleeding risk, but the TIA contraindication applies regardless of dose; intracranial hemorrhage risk is not eliminated by dose reduction.
• Option B: Option B is incorrect: continuing prasugrel and intensifying aspirin in a patient who has just had a TIA while on prasugrel amplifies the intracranial hemorrhage risk that constitutes the contraindication; high-dose aspirin plus prasugrel is not an appropriate management response.
• Option D: Option D is incorrect: the contraindication is not limited to prior (pre-drug) TIA; it applies to any TIA or stroke history including new events arising during therapy; holding and restarting is not supported; the drug must be permanently discontinued.

ANSWER: A

Rationale:

For the prasugrel-to-clopidogrel transition in the chronic maintenance phase (this patient is 8 months post-PCI), the 2017 international expert consensus document on P2Y12 inhibitor switching recommends giving a 600 mg clopidogrel loading dose at the time of the prasugrel switch. Because prasugrel's active thiol forms an irreversible covalent disulfide bond with P2Y12, the per-platelet inhibition is already locked in on previously exposed platelets; there is no ongoing plasma prasugrel or active metabolite presence that would block clopidogrel's active thiol from accessing newly released uninhibited platelets. The loading dose is therefore not blocked and ensures rapid P2Y12 coverage from newly released uninhibited platelets, which are being continuously released and represent the population available for clopidogrel binding. Ticagrelor 180 mg loading dose at the time of prasugrel cessation is an equally appropriate alternative; ticagrelor's allosteric binding site means no competition with prasugrel's binding site exists.

• Option B: Option B is incorrect: while prasugrel-inhibited platelets are indeed irreversibly blocked for their lifespan, newly released platelets (approximately 10 to 15% of the pool daily) are uninhibited; a loading dose of the replacement agent is essential to achieve rapid P2Y12 coverage on these new platelets; avoiding the loading dose leaves a gap in protection from the uninhibited platelet population.
• Option C: Option C is incorrect: aspirin bridging does not substitute for P2Y12 inhibition; COX-1 and P2Y12 are distinct antiplatelet pathways; a P2Y12 loading dose is required at transition, not deferred to maintenance dosing alone.
• Option D: Option D is incorrect: holding all P2Y12 inhibitors for 5 days at 8 months post-DES would create an unacceptable gap in stent protection; while the stent is more endothelialized at 8 months than at 2 months, stent thrombosis risk during P2Y12 withdrawal remains clinically significant; the transition should be immediate with a loading dose.

ANSWER: D

Rationale:

These are two pharmacologically and clinically distinct issues that the student has conflated. The 5 mg daily maintenance dose recommendation for patients weighing less than 60 kg addresses a weight-related pharmacokinetic concern: at standard 10 mg dosing, lower-weight patients have proportionally higher active metabolite exposure, and the TRITON-TIMI 38 trial demonstrated no net clinical benefit in the under-60 kg subgroup at 10 mg (excess bleeding offset ischemic benefit); dose reduction to 5 mg was recommended to improve the benefit-to-risk ratio in that weight-defined subgroup. This has nothing to do with the TIA/stroke contraindication. The TIA/stroke absolute contraindication is based on a completely separate finding from TRITON-TIMI 38: patients with prior stroke or TIA who received prasugrel had excess intracranial hemorrhage that produced net harm regardless of body weight or dose level. The FDA's boxed warning and formal contraindication does not specify that it applies only at 10 mg; it applies to prasugrel in any patient with prior stroke or TIA at any dose. The mechanism — excess intracranial hemorrhage in cerebrovascularly compromised patients — is not mitigated by reducing the dose from 10 to 5 mg. This patient's weight of 52 kg and her new TIA are both relevant but independently: the weight would have argued for 5 mg rather than 10 mg at initiation; the TIA now mandates discontinuation regardless of dose.

• Option A: Option A is incorrect: dose reduction does not paradoxically increase platelet-thrombin interactions; this mechanism is fabricated.
• Option B: Option B is incorrect: dose reduction can be applied at any time during therapy; there is no pharmacological adaptation of P2Y12 receptor density to inhibitor dose that would make retroactive dose adjustment problematic.
• Option C: Option C is incorrect: the statement describes dose reduction as simply "indicating" a weight threshold, but the key point — that the contraindication applies at any dose — is the critical distinction; option D more precisely and completely explains the pharmacological and regulatory basis for why dose reduction does not resolve the contraindication.

ANSWER: B

Rationale:

In the TRITON-TIMI 38 trial pre-specified subgroup analyses, three patient subgroups were identified in which prasugrel at standard 10 mg daily dosing showed no net clinical benefit compared to clopidogrel: patients with prior stroke or TIA (net harm, absolute contraindication), patients aged 75 years or older (no net benefit), and patients weighing less than 60 kg (no net benefit). In the less-than-60 kg subgroup, the ischemic benefit of prasugrel's more potent P2Y12 inhibition was offset by a proportionally greater increase in major bleeding, yielding no net clinical advantage over clopidogrel. This patient weighed 52 kg at the time of her index discharge, placing her in this low-weight, no-net-benefit subgroup. The prescribing information recommends considering a reduced maintenance dose of 5 mg daily in patients weighing less than 60 kg. At initiation, the prescriber should have either reduced the dose to 5 mg or selected an alternative P2Y12 inhibitor (clopidogrel or ticagrelor) instead of standard-dose prasugrel. Note that ticagrelor does not have a body-weight-based contraindication or dose adjustment, making it another appropriate option for this patient's original indication.

• Option A: Option A is incorrect: age 65 does not independently contraindicate prasugrel; the age-related no-net-benefit finding in TRITON-TIMI 38 applied to patients 75 years or older, not 65; renal impairment does not explain excess prasugrel bleeding through active metabolite accumulation in the manner described.
• Option C: Option C is incorrect: female sex is not an independent basis for avoiding prasugrel; no guideline recommends clopidogrel over prasugrel based on sex alone; the relevant weight finding is separate from sex.
• Option D: Option D is incorrect: prasugrel's FDA approval covers ACS patients undergoing PCI, which includes both NSTEMI and STEMI presentations; it is not restricted to STEMI-only PCI.

ANSWER: A

Rationale:

The AUGUSTUS trial (n = 4,614) used a 2×2 factorial design that included a direct comparison of apixaban 5 mg twice daily versus warfarin in AF patients with recent ACS or undergoing PCI, with all patients receiving a P2Y12 inhibitor. Apixaban produced significantly less clinically relevant or major bleeding than warfarin (10.5% vs. 14.7%) without significant differences in the ischemic composite endpoint of death, MI, or stroke. This patient is an ideal apixaban candidate: normal renal function, no mechanical valve, no antiphospholipid syndrome (conditions that mandate warfarin). Current ACC/AHA guidelines recommend DOAC preference over warfarin for eligible AF-PCI patients, with apixaban having the strongest direct evidence base from AUGUSTUS.

• Option B: Option B is incorrect: while anticoagulation reversibility is a legitimate clinical consideration, the superior bleeding safety of apixaban outweighs this theoretical advantage in most cases; furthermore, andexanet alfa (the apixaban reversal agent) has been approved and its availability is expanding; the AUGUSTUS evidence directly informs this clinical decision in favor of apixaban.
• Option C: Option C is incorrect: rivaroxaban 2.5 mg twice daily is the vascular protection dose studied in the COMPASS trial for stable atherosclerosis patients, not for AF stroke prevention; for AF, the standard anticoagulant dose (rivaroxaban 20 mg daily) is required, not the low vascular dose; rivaroxaban is not specifically approved for the combined AF-PCI indication based on the AUGUSTUS data, which evaluated apixaban.
• Option D: Option D is incorrect: dabigatran does require dose adjustment for renal impairment (reduced to 75 mg twice daily when CrCl is 15–30 mL/min); direct thrombin inhibition does not produce clinically meaningful antiplatelet effects through PAR-1 at therapeutic anticoagulant doses; the antiplatelet and anticoagulant components remain distinct.

ANSWER: C

Rationale:

The AUGUSTUS trial (n = 4,614) used a 2×2 factorial design that separately evaluated aspirin versus placebo (with all patients receiving OAC plus P2Y12 inhibitor). The aspirin-versus-placebo comparison demonstrated that adding aspirin to OAC plus P2Y12 inhibitor doubled clinically relevant bleeding events (BARC type 2, 3, or 5: 16.1% vs. 9.0%) without a statistically significant reduction in the composite ischemic endpoint. Aspirin is therefore the component that contributes disproportionate bleeding risk relative to ischemic protection in the maintenance phase of an OAC plus P2Y12 regimen. After the initial triple therapy period (typically 1 to 4 weeks, timed to cover the highest acute stent thrombosis risk), current ACC/AHA guidelines recommend transitioning to dual therapy consisting of the OAC (apixaban in this case) plus the P2Y12 inhibitor (clopidogrel preferred for its better-characterized bleeding profile in this context).

• Option A: Option A is incorrect: AUGUSTUS demonstrated the opposite — the P2Y12 inhibitor should be kept and aspirin dropped; the trial found no benefit to continuing aspirin beyond the initial period; clopidogrel is a necessary component for post-stent protection and is maintained.
• Option B: Option B is incorrect: apixaban is the irreplaceable component for AF stroke prevention; AF-related cardioembolic stroke is driven by fibrin-based left atrial thrombus requiring anticoagulation — dual antiplatelet therapy alone cannot substitute; omitting the OAC in an AF patient with CHA₂DS₂-VASc of 5 would expose him to unacceptably high stroke risk.
• Option D: Option D is incorrect: anticoagulation monotherapy without any antiplatelet agent after drug-eluting stent placement at 4 weeks carries an elevated stent thrombosis risk; P2Y12 inhibition remains essential for post-stent protection beyond the immediate procedural period; OAC monotherapy does not provide equivalent stent protection.

ANSWER: B

Rationale:

This patient has experienced a clinically significant GI bleed on triple therapy, and the regimen must be reduced. The evidence-based choice of which component to remove is directly informed by the AUGUSTUS trial: among AF patients with recent ACS or PCI on OAC plus P2Y12 inhibitor, adding aspirin doubled clinically relevant bleeding without reducing the composite ischemic endpoint. Aspirin is therefore the component with the least favorable benefit-to-bleeding-risk ratio in this combined regimen and is the appropriate agent to remove. Apixaban must be maintained for AF stroke prevention — a CHA₂DS₂-VASc of 5 represents very high embolic risk, and stopping anticoagulation to allow ulcer healing would expose this patient to unacceptably high risk of cardioembolic stroke. Clopidogrel must be maintained for post-stent P2Y12 coverage — at only 3 weeks post-DES, the stent is at its highest risk for thrombosis during any P2Y12 inhibitor interruption; discontinuing clopidogrel at this critical window carries a mortality risk from stent thrombosis that substantially exceeds the rebleeding risk after successful endoscopic hemostasis. Adding a PPI (if not already on one, or switching to a high-dose regimen) provides important GI mucosal protection going forward.

• Option A: Option A is incorrect: stopping all antithrombotic therapy for 2 weeks at 3 weeks post-DES carries an unacceptably high stent thrombosis risk; current guidance supports resuming antithrombotic therapy as soon as hemostasis is achieved after endoscopic treatment, not a 2-week cessation.
• Option C: Option C is incorrect: AUGUSTUS evidence does not support removing clopidogrel in favor of aspirin; the opposite is true — clopidogrel should be maintained and aspirin removed; and the mechanism described (P2Y12 inhibition impairing platelet-derived growth factor release) is not the established pharmacological reason to prefer aspirin over clopidogrel for mucosal healing.
• Option D: Option D is incorrect: cessation of all antithrombotic therapy for 4 weeks at 3 weeks post-DES is extremely high risk for stent thrombosis; the risk of fatal stent thrombosis substantially outweighs the rebleeding risk after successful endoscopic hemostasis; antithrombotic therapy should be resumed as soon as safely possible after hemostasis.

ANSWER: D

Rationale:

At 12 months post-DES, several considerations converge. The stent endothelialization process is largely complete for modern drug-eluting stents by 6 to 12 months, substantially reducing the incremental stent thrombosis risk that justified combined OAC plus P2Y12 inhibition in the earlier post-procedure period. For patients with AF who have completed the acute and sub-acute post-PCI window, current ACC/AHA and ESC guidelines recognize that transitioning to OAC monotherapy (dropping the antiplatelet component) at 12 months is an appropriate strategy for patients with stable CAD, low ongoing ischemic risk, or significant bleeding history — particularly given that this patient had a GI bleed. Anticoagulation with a DOAC provides meaningful antithrombotic coverage that reduces both AF-related embolic stroke and, to a lesser degree, coronary atherothrombotic events through its anticoagulant mechanism. This must be individualized: patients with recent ACS, multiple stents, complex stent anatomy, or high residual ischemic risk may warrant continued OAC plus antiplatelet therapy beyond 12 months.

• Option A: Option A is incorrect: aspirin monotherapy provides neither adequate AF stroke prevention (AF-related stroke requires anticoagulation, not antiplatelet therapy) nor adequate post-stent secondary prevention; this approach exposes the patient to unacceptably high stroke and recurrent coronary event risk.
• Option B: Option B is incorrect: indefinite OAC plus P2Y12 inhibitor dual therapy for all AF-PCI patients beyond 12 months is not the guideline standard; at the 12-month mark for stable post-PCI patients with low ongoing ischemic risk, transitioning to OAC monotherapy is an appropriate and guideline-recognized option; indefinite dual therapy increases bleeding burden without commensurate benefit in this stable phase.
• Option C: Option C is incorrect: re-adding aspirin beyond 12 months is not supported by AUGUSTUS; the trial demonstrated that aspirin doubles bleeding without reducing ischemia; this finding applies to the maintenance phase and does not reverse at 12 months; aspirin should not be reintroduced in this OAC-based regimen.

ANSWER: D

Rationale:

GP IIb/IIIa inhibitor-associated thrombocytopenia is a class-specific immune reaction mediated by naturally occurring antibodies recognizing LIBS (ligand-induced binding site) neoepitopes. In resting platelets, GP IIb/IIIa (integrin alphaIIb beta3) is maintained in a closed, low-affinity conformation; when tirofiban (or any GP IIb/IIIa inhibitor) occupies the receptor, it induces a conformational change that exposes structural epitopes not present on the unoccupied receptor. Critically, some individuals carry pre-formed circulating immunoglobulins that bind exactly these drug-induced neoepitopes — these antibodies arose independently of any prior GP IIb/IIIa inhibitor exposure, possibly through cross-reactivity with unrelated environmental antigens. When the drug is administered for the first time and LIBS neoepitopes are exposed, the pre-formed antibodies bind immediately, coating drug-bound platelets and triggering Fc receptor-mediated reticuloendothelial clearance within 2 to 24 hours. This mechanism explains why first-exposure, acute profound thrombocytopenia can occur — no sensitization is required because the responsible antibodies preexist. This reaction occurs with all three GP IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) and is not unique to abciximab's murine-derived sequences.

• Option A: Option A is incorrect: complement-mediated platelet lysis through the alternative pathway is not the established mechanism; the LIBS neoepitope-antibody mechanism is the accepted explanation; complement activation is not a described pathway for GP IIb/IIIa inhibitor thrombocytopenia.
• Option B: Option B is incorrect: acute HIT within 5 hours is only possible in patients previously sensitized to heparin within approximately the prior 100 days; this patient has no prior heparin exposure by history; and the 5-hour timing is characteristic of GP IIb/IIIa inhibitor thrombocytopenia, not of delayed-onset HIT in a previously naive patient.
• Option C: Option C is incorrect: supratherapeutic tirofiban concentrations producing concentration-dependent non-immune platelet clearance is not an established mechanism; GP IIb/IIIa inhibitor thrombocytopenia is immune-mediated, not a direct effect of receptor blockade stoichiometry.

ANSWER: B

Rationale:

GP IIb/IIIa inhibitor-induced thrombocytopenia requires immediate cessation of the offending drug. The first management steps are: stop tirofiban; stop heparin pending exclusion of concurrent HIT (since both drugs were given and HIT must be excluded — HIT antibody testing should be sent); confirm the thrombocytopenia is real (already done in this case via citrate tube); and monitor the platelet count closely. Because this patient has no active bleeding and is hemodynamically stable at a count of 12,000/mcL, immediate platelet transfusion is not mandated — it is reserved for patients with serious bleeding or those requiring urgent invasive procedures. The thrombocytopenia from GP IIb/IIIa inhibitors typically begins to resolve within 24 to 48 hours of stopping the drug as immune complex clearance and new platelet production restore the count. The patient should not be rechallenged with tirofiban or any other GP IIb/IIIa inhibitor, as prior exposure increases the risk and severity of repeat thrombocytopenia.

• Option A: Option A is incorrect: continuing tirofiban in the setting of drug-induced immune thrombocytopenia is contraindicated; the drug is the causative agent and must be stopped; administering platelets while tirofiban is infusing provides only partial benefit as circulating drug will occupy and inhibit GP IIb/IIIa on transfused platelets.
• Option C: Option C is incorrect: dose reduction does not treat the immune-mediated mechanism; the LIBS neoepitope antibody reaction persists as long as the drug occupies receptors, regardless of dose; corticosteroids are not an established effective treatment for GP IIb/IIIa inhibitor thrombocytopenia and are not part of standard management.
• Option D: Option D is incorrect: profound thrombocytopenia from GP IIb/IIIa inhibitor toxicity does not cause a consumptive coagulopathy requiring FFP and cryoprecipitate; these agents replace coagulation factors, not platelets; FFP is not indicated for isolated thrombocytopenia without concurrent coagulopathy.

ANSWER: C

Rationale:

Tirofiban is a non-peptide mimetic that is eliminated primarily by renal excretion, with approximately 65% of the drug excreted unchanged in the urine. Dose adjustment is required when CrCl falls below 30 mL/min: the infusion rate is reduced by 50% (from the standard 0.15 mcg/kg/min to 0.075 mcg/kg/min in the high-dose regimen). At a CrCl of 22 mL/min, this patient was at the level requiring dose reduction; using the full infusion rate would have produced significantly elevated tirofiban exposure. Abciximab, by contrast, is a large monoclonal antibody Fab fragment that is eliminated through platelet binding and redistribution across the circulating platelet pool; renal clearance plays a negligible role in its disposition, and no dose adjustment is required for any degree of renal impairment. Eptifibatide is also substantially renally eliminated (approximately 50% unchanged in urine) and requires infusion rate halving at CrCl 10–50 mL/min, with contraindication below CrCl 10 mL/min or in dialysis patients.

• Option A: Option A is incorrect: tirofiban is not primarily hepatically eliminated by CYP3A4; it is predominantly renally excreted; renal impairment substantially increases tirofiban exposure and dose adjustment is required.
• Option B: Option B is incorrect: the three agents do not require equivalent dose adjustments; abciximab requires no renal adjustment; eptifibatide requires adjustment at CrCl 10–50 mL/min; tirofiban requires adjustment at CrCl below 30 mL/min; the thresholds and mechanisms differ across the class.
• Option D: Option D is incorrect: tirofiban is not absolutely contraindicated at CrCl below 25 mL/min; dose reduction with careful monitoring is the recommendation; abciximab does not have a formal approval advantage specifically for CrCl below 25 mL/min — its preferability reflects its renal-independent disposition, not a regulatory approval specifically for that CrCl threshold.

ANSWER: A

Rationale:

GP IIb/IIIa inhibitor-associated thrombocytopenia is a class effect mediated by LIBS (ligand-induced binding site) neoepitope antibodies. While the specific epitopes exposed may vary somewhat across the three agents — abciximab (chimeric Fab fragment), eptifibatide (cyclic heptapeptide), and tirofiban (non-peptide mimetic) — the underlying mechanism of drug-induced conformational change exposing neoepitopes is shared across the class. Prior exposure to one GP IIb/IIIa inhibitor can sensitize the patient to other members of the class through cross-reactive LIBS epitopes, and prior thrombocytopenia is considered a risk factor for recurrent and potentially more severe thrombocytopenia on re-exposure to any GP IIb/IIIa inhibitor. If a future procedure requires a GP IIb/IIIa inhibitor and no alternative is available, the standard monitoring protocol — baseline platelet count before initiation and a repeat count at 2 to 4 hours after the first dose — is mandatory; daily counts should be obtained during any infusion. The patient and procedural team must be prepared for the possibility of acute profound thrombocytopenia.

• Option B: Option B is incorrect: cross-reactivity between GP IIb/IIIa inhibitors for LIBS neoepitope thrombocytopenia has been documented; the antibodies are directed at the GP IIb/IIIa receptor in its drug-bound conformation, not specifically against the drug's chemical scaffold; structural dissimilarity of the drugs does not prevent cross-reactivity at the receptor-level neoepitopes.
• Option C: Option C is incorrect: LIBS neoepitope thrombocytopenia is an antibody-mediated immune reaction, not a constitutive platelet hypersensitivity state; high-dose corticosteroids and antihistamines are not validated as prevention strategies for GP IIb/IIIa inhibitor thrombocytopenia and should not be relied upon to attenuate the reaction to a safe level.
• Option D: Option D is incorrect: the immunological memory for LIBS neoepitope antibodies does not predictably decay within 3 to 6 months; prior exposure is considered a persisting risk factor; the 6-month window described as conferring safety is not supported by pharmacological evidence; platelet monitoring is required regardless of the time since the prior reaction.

ANSWER: C

Rationale:

The PRECISE-DAPT score was developed and validated to predict bleeding risk at 12 months in patients undergoing coronary stent implantation, incorporating five variables: age, creatinine clearance, hemoglobin, white blood cell count, and prior spontaneous bleeding. This patient's score of 28 — driven by his reduced CrCl of 34 mL/min and low hemoglobin — exceeds the validated threshold of 25, which identifies patients for whom shortened DAPT (3 to 6 months) is the preferred strategy. This recommendation applies most compellingly in the elective (non-ACS) setting with new-generation DES, where the stent design's lower thrombogenicity makes shorter DAPT durations safer than with older-generation stents. The PRECISE-DAPT score was validated in both ACS and stable CAD populations undergoing PCI; it is not restricted to ACS patients.

• Option A: Option A is incorrect: the PRECISE-DAPT score applies to both ACS and stable CAD populations; a blanket 12-month recommendation ignores validated risk-scoring evidence; current guidelines explicitly support shorter DAPT (1 to 3 months acceptable, 3 to 6 months standard for high-risk) in patients with new-generation DES and high bleeding risk scores.
• Option B: Option B is incorrect: the PRECISE-DAPT score predicts bleeding risk specifically — a high score indicates high bleeding risk and supports shorter DAPT, not longer; the score does not measure ischemic risk; CKD and anemia elevate bleeding risk, not ischemic risk, in this scoring context.
• Option D: Option D is incorrect: a high PRECISE-DAPT score does not constitute an absolute contraindication to P2Y12 inhibitor use; after coronary stent placement, dual antiplatelet therapy is required for at least some duration to prevent stent thrombosis; aspirin monotherapy without P2Y12 inhibition is insufficient stent protection.

ANSWER: B

Rationale:

The DAPT Score is applied at 12 months to patients who have tolerated their DAPT course without a bleeding event, to determine whether extension beyond that point provides net clinical benefit. The score incorporates nine variables and the validated decision threshold is 2: scores of 2 or above predict that the ischemic benefit of prolonged DAPT outweighs the bleeding risk, favoring extension; scores below 2 predict no net benefit from extension. This patient's DAPT Score of 1 falls below the threshold, indicating that he is not predicted to derive net ischemic benefit from continued P2Y12 inhibition beyond 12 months. The appropriate recommendation is to discontinue the P2Y12 inhibitor and continue aspirin monotherapy for indefinite secondary prevention. His stable CAD presentation (no prior MI, no diabetes, no CHF, no prior PCI, age 63) contributes to the low score reflecting lower ischemic risk.

• Option A: Option A is incorrect: the DAPT Score does not require supplemental platelet function testing for scores of 1; the threshold of 2 is the validated action boundary, not an uncertain zone; scores below 2 have a defined clinical recommendation (no extension) without additional testing.
• Option C: Option C is incorrect: a DAPT Score of 1 below the threshold of 2 does not support extension; the threshold is not a "minimum" below which some benefit still exists — it is the evidence-based cut-point separating those who benefit from extension (≥2) from those who do not (<2).
• Option D: Option D is incorrect: while the DAPT Score was originally derived in patients completing 12 months of DAPT in the DAPT trial, its application in clinical practice is not strictly limited to patients who received exactly 12 months; this patient has now reached the 12-month post-PCI timepoint regardless of when DAPT was shortened, and the score provides useful risk stratification at this clinical decision point.

ANSWER: D

Rationale:

The TWILIGHT trial (n = 7,119) randomized high-risk PCI patients who had completed 3 months of DAPT with ticagrelor plus aspirin without a major ischemic or bleeding event to ticagrelor plus placebo (aspirin stopped) or ticagrelor plus aspirin continued for 12 additional months. The primary endpoint — clinically relevant bleeding (BARC type 2, 3, or 5) — was reduced by 44% in the ticagrelor monotherapy group (4.0% vs. 7.1%), while the composite ischemic endpoint of death, MI, or stroke was not significantly different between arms (3.9% vs. 3.9%). TWILIGHT enrolled high-risk PCI patients defined by clinical features (ACS) or angiographic high-risk features (multivessel disease, bifurcation stenting, calcified lesions, long stent, small vessel); this patient undergoing elective PCI with a high bleeding risk score may qualify depending on his specific angiographic features. The conceptual basis for stopping aspirin rather than ticagrelor is that aspirin's COX-1 inhibition contributes disproportionately to gastrointestinal mucosal injury during the maintenance phase, while ticagrelor's P2Y12 inhibition provides more relevant protection against ADP-mediated stent thrombosis. For a patient on ticagrelor who has completed 3 months of uneventful DAPT, this de-escalation strategy is pharmacologically sound and trial-supported.

• Option A: Option A is incorrect: while TWILIGHT enrolled high-risk PCI patients using defined clinical and angiographic criteria, stable CAD patients with high-risk angiographic features were enrolled; the de-escalation strategy is not restricted to ACS and is applicable when high-risk eligibility criteria are met.
• Option B: Option B is incorrect: the TWILIGHT trial did not set a specific PRECISE-DAPT score threshold for enrollment; the 28 vs. 30 distinction described is not a defined enrollment criterion; the trial's eligibility was based on clinical and angiographic high-risk features, not PRECISE-DAPT score ranges.
• Option C: Option C is incorrect: TWILIGHT specifically evaluated ticagrelor monotherapy (not clopidogrel); ticagrelor is the P2Y12 inhibitor for which the strongest de-escalation evidence exists from TWILIGHT; the STOPDAPT-2 trial evaluated clopidogrel monotherapy after 1 month of DAPT, which is a different protocol; the two trials are complementary, not competing, and ticagrelor monotherapy is the evidence-based strategy when the patient is already on ticagrelor.

ANSWER: A

Rationale:

The clinically significant drug interaction between PPIs and P2Y12 inhibitors applies specifically to clopidogrel, which requires two sequential CYP2C19-mediated oxidation steps to generate its active thiol metabolite; CYP2C19 inhibition by omeprazole or esomeprazole reduces clopidogrel bioactivation and platelet inhibition. Ticagrelor is a direct-acting cyclopentyl-triazolo-pyrimidine that does not require CYP2C19 bioactivation — it is absorbed and acts directly as the parent compound at the P2Y12 allosteric site. Approximately 30 to 40% of ticagrelor's antiplatelet activity is attributable to its active metabolite AR-C124910XX, which is generated by CYP3A4 (not CYP2C19); omeprazole does not significantly inhibit CYP3A4 at therapeutic doses. Therefore, CYP2C19 inhibition by omeprazole has no pharmacologically meaningful effect on ticagrelor's antiplatelet efficacy, and no PPI substitution is required. The pharmacist's concern is appropriate vigilance but reflects the class interaction warning written for clopidogrel that does not apply to ticagrelor. Pantoprazole remains a reasonable generic preference for PPI prescribing given its CYP2C19 neutrality, but there is no pharmacological mandate to substitute when the P2Y12 inhibitor is ticagrelor.

• Option B: Option B is incorrect: the P2Y12-PPI interaction is not a class effect of all P2Y12 inhibitors; prasugrel and ticagrelor have substantially less CYP2C19 dependence; ticagrelor has none relevant to its antiplatelet effect; the interaction is specifically a clopidogrel (prodrug) concern.
• Option C: Option C is incorrect: ticagrelor does not share a metabolic pathway with PPIs through CYP2C19; PPIs as a class do not reduce ticagrelor exposure; ranitidine substitution is not required and ranitidine (an H2 antagonist) is a less effective acid suppressant for most reflux presentations.
• Option D: Option D is incorrect: omeprazole does not inhibit CYP3A4 (the enzyme responsible for AR-C124910XX formation); it inhibits CYP2C19; dose escalation of omeprazole would not reduce ticagrelor's active metabolite levels; this reasoning is pharmacologically incorrect.

ANSWER: A

Rationale:

This case presents two simultaneous high-risk situations that create genuine conflict. First, ticagrelor at 24 to 48 hours post-last-dose still produces meaningful P2Y12 inhibition: while platelet function begins recovering relatively promptly as plasma ticagrelor concentrations decline (approximately 50% recovery requires 24 to 48 hours), recovery to near-normal levels suitable for surgical hemostasis requires closer to 5 days. Operating at 24 to 48 hours of hold significantly elevates intraoperative and postoperative bleeding risk compared to a full hold. Second, this patient is at only 6 weeks post-DES — squarely within the highest-risk window for stent thrombosis during P2Y12 inhibitor interruption; drug-eluting stents have incomplete re-endothelialization at 6 weeks, and even brief P2Y12 withdrawal during this period carries meaningful stent thrombosis risk (with mortality rate 20 to 45% for stent thrombosis). Neither risk is trivial, and the correct management framework is urgent cardiology-surgical co-management with explicit risk communication to the patient. Cangrelor IV bridging (discussed in Q2) may be considered to maintain P2Y12 coverage right up to the moment of incision.

• Option B: Option B is incorrect: full platelet function does not recover within 24 hours of ticagrelor cessation; approximately 50% recovery occurs at 24 to 48 hours; surgical-level hemostasis typically requires closer to 5 days; the ACC/AHA guidelines do not provide a formal 24-hour emergency exception for ticagrelor.
• Option C: Option C is incorrect: desmopressin releases stored vWF from endothelial Weibel-Palade bodies and improves platelet adhesion in bleeding disorders such as uremia or von Willebrand disease, but it does not reverse P2Y12 inhibition; it does not overcome ticagrelor's direct blockade of ADP-mediated platelet activation.
• Option D: Option D is incorrect: continuing all antiplatelet agents through abdominal surgery for perforated diverticulitis would produce unacceptable intraoperative and postoperative bleeding risk; general anesthesia does not have anticoagulant properties that protect surgical hemostasis; antiplatelet agents cannot be safely continued through this operation.

ANSWER: D

Rationale:

Cangrelor is an intravenous ATP analogue that directly and reversibly inhibits P2Y12. Its key pharmacokinetic features that enable perioperative bridging are: near-immediate onset (near-maximal platelet inhibition within minutes of starting the infusion, because it is a direct-acting agent requiring no bioactivation) and rapid, predictable offset (platelet function returns to near-baseline within 60 to 90 minutes of stopping, because the reversible binding dissipates as drug concentrations fall rapidly with a plasma half-life of approximately 3 to 5 minutes). This combination — immediate onset and 60 to 90 minute offset — allows the bridging protocol to maintain P2Y12 coverage until approximately 1 hour before incision, then stop the infusion and proceed to surgery with platelet function substantially restored at the time of the first incision. No other IV antiplatelet agent provides this combination of speed and predictable reversibility. After surgery, when the surgical team has achieved hemostasis and is comfortable with wound integrity, oral P2Y12 therapy is reloaded and cangrelor can be restarted to bridge until the oral agent achieves adequate platelet inhibition.

• Option A: Option A is incorrect: cangrelor's plasma half-life is approximately 3 to 5 minutes, not 6 to 8 hours; it is one of the most rapidly eliminated drugs in clinical use; its offset occurs through rapid drug clearance as soon as the infusion stops, not through a gradual 4 to 6 hour decline.
• Option B: Option B is incorrect: cangrelor is exclusively an intravenous agent; it is not available in an oral formulation and has negligible oral bioavailability; its pharmacokinetic properties that make it useful as a bridging agent depend on IV administration.
• Option C: Option C is incorrect: the mechanism of cangrelor's rapid offset is straightforward drug elimination through rapid plasma clearance (half-life approximately 3 to 5 minutes), not protein sequestration; the reversible binding at P2Y12 dissipates as plasma concentrations fall during drug elimination.

ANSWER: C

Rationale:

Post-operative P2Y12 management after perioperative bridging requires balancing surgical bleeding risk against stent thrombosis risk. The general principle is to restart oral P2Y12 therapy as soon as the surgical team is confident that hemostasis is secure and the patient can safely receive antiplatelet therapy — typically within 12 to 48 hours post-operatively for most elective and urgent procedures, depending on the surgical site and procedure. For ticagrelor, a 180 mg loading dose is appropriate at restart to achieve rapid receptor occupancy, particularly in this high-risk early post-stent patient; waiting for maintenance dosing to build up to steady state over several days is not appropriate when stent thrombosis risk is high. During the interval between cangrelor cessation and the onset of oral ticagrelor effect (approximately 1 to 2 hours for absorption and distribution after the loading dose), cangrelor can be used as a bridge: cangrelor is restarted after the surgical procedure, and ticagrelor is given orally once the patient can take medications; because ticagrelor binds an allosteric site distinct from cangrelor's orthosteric site, ticagrelor can be given during the cangrelor infusion — when cangrelor is stopped, ticagrelor (already distributed to its receptor site) provides ongoing P2Y12 coverage without a gap.

• Option A: Option A is incorrect: a mandatory 7-day P2Y12-free window after GI surgery is not a guideline recommendation; delaying P2Y12 reinitiation for 7 days at 6 weeks post-DES creates an unacceptable stent thrombosis risk window; the timing is determined by hemostasis status, not by a fixed post-operative interval.
• Option B: Option B is incorrect: restarting ticagrelor immediately without surgical team assessment of hemostasis could cause life-threatening surgical site bleeding before anastomotic integrity is confirmed; joint decision-making between cardiology and surgery is required; stent thrombosis risk must be weighed against active surgical bleeding risk.
• Option D: Option D is incorrect: a ticagrelor loading dose is not contraindicated post-operatively in all circumstances; the decision depends on the hemostatic situation; a loading dose is appropriate and recommended when rapid P2Y12 re-establishment is needed and hemostasis is confirmed.

ANSWER: B

Rationale:

The perioperative management of aspirin in post-coronary stent patients undergoing non-cardiac surgery involves balancing surgical bleeding risk against the benefit of maintaining some degree of platelet inhibition during the period when the P2Y12 inhibitor is held. Current perioperative guidelines and cardiology-surgery co-management recommendations generally support continuing aspirin through surgery in patients with recent coronary stents (particularly within the first 6 to 12 months post-DES), with specific exceptions for procedures where even minimal platelet dysfunction could be catastrophic (e.g., intracranial or posterior segment ophthalmic surgery). The rationale is that while ticagrelor is held to restore P2Y12-mediated platelet aggregation for surgical hemostasis, aspirin's COX-1 inhibition provides partial but meaningful antithrombotic protection during the P2Y12 hold window, reducing (though not eliminating) stent thrombosis risk. The bleeding contribution of aspirin alone in laparoscopic colonic surgery is generally manageable, and the benefit of maintaining this residual antiplatelet protection typically outweighs the incremental bleeding risk. The surgical team should be informed of aspirin continuation and prepared for this contribution to hemostasis.

• Option A: Option A is incorrect: a 10-day aspirin hold and 7-day post-operative delay are not the recommended approach for a patient at high stent thrombosis risk at 6 weeks post-DES; stopping aspirin for this extended period removes the only remaining antithrombotic protection during the cangrelor-free and ticagrelor-free window.
• Option C: Option C is incorrect: COX-2-selective inhibitors such as celecoxib do not provide meaningful antiplatelet protection; platelet TXA2 synthesis is mediated by COX-1, not COX-2; platelets express only COX-1 (anucleate, cannot upregulate COX-2); celecoxib does not substitute for aspirin's antiplatelet mechanism and provides no stent thrombosis protection.
• Option D: Option D is incorrect: cangrelor and aspirin address different platelet activation pathways — cangrelor blocks P2Y12 (ADP-mediated activation) and aspirin blocks COX-1 (TXA2-mediated activation); they are complementary, not redundant; stopping aspirin while cangrelor is running removes the COX-1 inhibitory protection; furthermore, cangrelor is stopped before incision, leaving a window where aspirin's continued presence is the only remaining antiplatelet agent.

ANSWER: B

Rationale:

Cilostazol is a selective PDE3 inhibitor that inhibits cAMP degradation in platelets, vascular smooth muscle cells, and cardiac myocytes. In platelets and vascular smooth muscle, elevated cAMP produces the desired antiplatelet and vasodilatory effects. In cardiac myocytes, elevated cAMP activates protein kinase A, producing positive inotropic and chronotropic effects with potential for increased arrhythmia and adverse myocardial remodeling — the same mechanism by which the inodilator PDE3 inhibitors milrinone and enoximone demonstrated significantly increased mortality in chronic heart failure trials. The cilostazol prescribing information carries a formal contraindication in heart failure of any severity — explicitly including HFpEF, without restriction to reduced ejection fraction or symptomatic heart failure. This patient's echocardiographically confirmed HFpEF with elevated BNP (confirming elevated filling pressures and the clinical heart failure diagnosis) satisfies this contraindication regardless of her ejection fraction of 42%.

• Option A: Option A is incorrect: prior stroke is not a listed contraindication to cilostazol; cilostazol's vasodilatory mechanism does not specifically increase recurrent stroke risk; the drug is used in some East Asian stroke prevention contexts; this is not the correct contraindication.
• Option C: Option C is incorrect: aspirin and cilostazol are commonly co-prescribed in vascular patients and there is no formally contraindicated drug combination between them; the pharmacodynamic interaction does not constitute a listed contraindication.
• Option D: Option D is incorrect: age above 65 is not a contraindication to cilostazol; dehydro-cilostazol accumulation in elderly patients is not the basis for an age-related contraindication; dose adjustment guidelines are based on renal and hepatic function, not age.

ANSWER: A

Rationale:

Vorapaxar is a PAR-1 (protease-activated receptor-1) antagonist approved for secondary prevention in patients with prior MI (myocardial infarction) or PAD, with the absolute exclusion of any patient with prior stroke or TIA. In the TRA 2°P-TIMI 50 trial (n = 26,449), the subgroup of patients with prior stroke or TIA who received vorapaxar had markedly elevated rates of intracranial hemorrhage that produced net clinical harm — the increase in intracranial hemorrhage substantially outweighed the reduction in MI and stent thrombosis. This finding is reflected as a boxed warning in the FDA prescribing information, with prior stroke or TIA listed as an absolute contraindication. The contraindication applies regardless of time elapsed since the stroke, the degree of neurological recovery, or whether the patient's PAD independently qualifies for vorapaxar under its approved indication. This patient had an ischemic stroke 2 years ago with full recovery — the absolute contraindication still applies.

• Option B: Option B is incorrect: HFpEF is not a listed contraindication to vorapaxar; PAR-1 antagonism does not produce hemodynamically meaningful vasodilation through thrombin-vascular tone mechanisms at the approved dose; there is no heart failure warning in the vorapaxar prescribing information.
• Option C: Option C is incorrect: vorapaxar is approved for use in combination with aspirin (the TRA 2°P-TIMI 50 trial included patients on aspirin); it is not contraindicated with aspirin; standard use of vorapaxar involves adding it to an aspirin-based antiplatelet regimen.
• Option D: Option D is incorrect: the prescribing information does not create a "PAD plus stroke" relative contraindication subcategory; the absolute contraindication is simply prior stroke or TIA in any patient, including those with PAD; having PAD does not modify the stroke-related contraindication.

ANSWER: D

Rationale:

The CAPRIE trial (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events, n = 19,185) compared clopidogrel 75 mg daily to aspirin 325 mg daily in patients with recent MI, recent ischemic stroke, or established PAD, demonstrating a modest but statistically significant relative risk reduction of 8.7% (P = 0.043) in the composite endpoint of ischemic stroke, MI, or vascular death in favor of clopidogrel. The benefit was greatest in the PAD subgroup (relative risk reduction 23.8%), making clopidogrel the preferred antiplatelet agent specifically for PAD secondary prevention per ACC/AHA PAD guidelines. For this patient with both PAD and prior ischemic stroke, clopidogrel is the appropriate antiplatelet choice: it is guideline-supported for PAD, also guideline-recommended for non-cardioembolic ischemic stroke or TIA secondary prevention (equivalent to ER-DP/ASA per current guidelines), and carries no stroke/TIA contraindication. Switching from aspirin to clopidogrel monotherapy is appropriate.

• Option A: Option A is incorrect: high-dose aspirin (325 mg) does not provide more effective secondary prevention than low-dose aspirin for atherothrombotic events; higher aspirin doses increase GI bleeding risk without proportional ischemic benefit; COX-2 inhibition in inflammatory cells is the anti-inflammatory mechanism of higher doses, not an antiplatelet advantage.
• Option B: Option B is incorrect: ticagrelor 90 mg twice daily added to aspirin in PEGASUS-TIMI 54 enrolled patients with prior MI more than 1 year earlier; this patient has no MI history; additionally, ticagrelor's indication in PEGASUS does not extend to patients with prior stroke, and adding ticagrelor to aspirin in a patient with prior stroke is not guideline-supported and would introduce a drug associated with higher bleeding risk than clopidogrel in this vulnerable population.
• Option C: Option C is incorrect: while clopidogrel is preferred over aspirin for PAD, the CAPRIE trial compared each drug as monotherapy rather than establishing DAPT as standard; routine DAPT (aspirin plus clopidogrel) for stable PAD without a recent coronary or cerebrovascular event is not guideline-recommended and was shown in CHARISMA to increase bleeding without reducing ischemic events in stable atherosclerotic patients.

ANSWER: C

Rationale:

Extended-release dipyridamole plus aspirin (ER-DP/ASA, Aggrenox) is a guideline-recommended first-line option for secondary prevention of non-cardioembolic ischemic stroke or TIA, representing an appropriate alternative to clopidogrel for this indication. Dipyridamole's antiplatelet mechanism involves two distinct pathways: (1) inhibition of PDE5 (cGMP-specific phosphodiesterase type 5) in platelets, preventing cGMP degradation and raising platelet cGMP, which activates protein kinase G and inhibits platelet activation; (2) inhibition of ENT1 (equilibrative nucleoside transporter 1), the cellular adenosine reuptake transporter, increasing local extracellular adenosine concentrations; elevated adenosine stimulates platelet adenylyl cyclase through A2A receptors (Gs-coupled), raising platelet cAMP and further inhibiting platelet activation through protein kinase A. These two mechanisms are mechanistically complementary with aspirin's COX-1 inhibition. The ESPRIT trial demonstrated ER-DP/ASA superiority over aspirin alone for secondary prevention of non-cardioembolic stroke/TIA, and the PRoFESS trial demonstrated statistical non-inferiority of ER-DP/ASA compared to clopidogrel. Current AHA/ASA stroke prevention guidelines recommend both ER-DP/ASA and clopidogrel monotherapy as acceptable first-line options for non-cardioembolic stroke/TIA secondary prevention, with aspirin alone considered inferior to either.

• Option A: Option A is incorrect: dipyridamole is not a P2Y12 antagonist; its mechanism involves PDE5 inhibition and adenosine reuptake inhibition; it has no direct binding activity at the P2Y12 receptor; aspirin also does not have a P2Y12 mechanism.
• Option B: Option B is incorrect: ER-DP/ASA was studied in non-cardioembolic stroke populations; the ESPRIT trial enrolled patients with non-cardioembolic TIA or minor stroke, not cardioemoblic events; dipyridamole's antiplatelet mechanism is entirely platelet-based and not mechanism-specific to cardioembolic events.
• Option D: Option D is incorrect: dipyridamole primarily inhibits PDE5 (cGMP-specific isoform) and adenosine reuptake — not PDE3; cilostazol and milrinone are PDE3 inhibitors; dipyridamole's phosphodiesterase specificity is PDE5, not PDE3; the heart failure contraindication specific to PDE3 inhibitors does not apply to dipyridamole at antiplatelet doses.